| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $1,512,590 | 12 | 100 |
| Milligan Michael Lee | See Remarks | 0 | $0 | 1 | $3,351 | $-3,351 |
| Pinto Joshua | President | 0 | $0 | 1 | $13,477 | $-13,477 |
| Aurora Daljit Singh | Chief Strategy Officer | 0 | $0 | 1 | $14,347 | $-14,347 |
| BERNS PAUL L | See Remarks | 0 | $0 | 1 | $23,468 | $-23,468 |
| Fust Matthew K | director | 0 | $0 | 2 | $370,962 | $-370,962 |
| Lenz Robert A. | Head of R&D | 0 | $0 | 6 | $1.09M | $-1.09M |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Over the last 12 months, insiders at Neumora Therapeutics, Inc. Common Stock have bought $0 and sold $1.51M worth of Neumora Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Neumora Therapeutics, Inc. Common Stock have bought $63.05M and sold $1.51M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,357 shares for transaction amount of $40,217 was made by Burow Kristina () on 2023‑11‑14.
| 2025-02-18 | Sale | BERNS PAUL L | See Remarks | 13,871 0.0083% | $1.69 | $23,468 | -53.29% | |
| 2025-02-18 | Sale | Lenz Robert A. | Head of R&D | 5,614 0.0033% | $1.67 | $9,383 | -53.29% | |
| 2025-02-18 | Sale | Aurora Daljit Singh | Chief Strategy Officer | 8,565 0.0051% | $1.68 | $14,347 | -53.29% | |
| 2025-02-18 | Sale | Pinto Joshua | President | 8,048 0.0048% | $1.67 | $13,477 | -53.29% | |
| 2025-02-18 | Sale | Milligan Michael Lee | See Remarks | 1,978 0.0012% | $1.69 | $3,351 | -53.29% | |
| 2024-10-18 | Sale | Fust Matthew K | director | 14,049 0.0149% | $17.03 | $239,319 | -90.96% | |
| 2024-10-17 | Sale | Fust Matthew K | director | 7,739 0.0082% | $17.01 | $131,643 | -91.13% | |
| 2024-10-10 | Sale | Lenz Robert A. | Head of R&D | 8,260 0.0078% | $15.09 | $124,603 | -89.94% | |
| 2024-10-09 | Sale | Lenz Robert A. | Head of R&D | 5,563 0.0052% | $15.01 | $83,507 | -89.13% | |
| 2024-09-18 | Sale | Lenz Robert A. | Head of R&D | 10,676 0.008% | $12.09 | $129,091 | -86.00% | |
| 2024-09-17 | Sale | Lenz Robert A. | Head of R&D | 30,788 0.0226% | $11.81 | $363,736 | -85.42% | |
| 2024-09-12 | Sale | Lenz Robert A. | Head of R&D | 32,948 0.0235% | $11.43 | $376,665 | -85.38% | |
| 2023-11-14 | Burow Kristina | 3,357 0.0025% | $11.98 | $40,217 | +3.37% | |||
| 2023-11-14 | ARCH Venture Partners XII, LLC | 10 percent owner | 3,357 0.0025% | $11.98 | $40,217 | +3.37% | ||
| 2023-11-13 | Burow Kristina | 31,653 0.0232% | $11.75 | $371,923 | +2.51% | |||
| 2023-11-13 | ARCH Venture Partners XII, LLC | 10 percent owner | 31,653 0.0232% | $11.75 | $371,923 | +2.51% | ||
| 2023-11-10 | Burow Kristina | 17,275 0.0124% | $11.49 | $198,481 | +5.87% | |||
| 2023-11-10 | ARCH Venture Partners XII, LLC | 10 percent owner | 17,275 0.0124% | $11.49 | $198,481 | +5.87% | ||
| 2023-11-09 | Burow Kristina | 31,079 0.0204% | $10.53 | $327,262 | +15.57% | |||
| 2023-11-09 | ARCH Venture Partners XII, LLC | 10 percent owner | 31,079 0.0204% | $10.53 | $327,262 | +15.57% |
| BERNS PAUL L | See Remarks | 7405004 4.5781% | $13.7M | 0 | 1 | |
| Lenz Robert A. | Head of R&D | 309092 0.1911% | $571,820.20 | 0 | 6 | |
| Aurora Daljit Singh | Chief Strategy Officer | 88935 0.055% | $164,529.75 | 0 | 1 | |
| Pinto Joshua | President | 76952 0.0476% | $142,361.20 | 0 | 1 | |
| Milligan Michael Lee | See Remarks | 22470 0.0139% | $41,569.50 | 0 | 1 | |
| Fust Matthew K | director | 20100 0.0124% | $37,185.00 | 0 | 2 | |
| Burow Kristina | 4131207 2.5541% | $7.64M | 15 | 0 | +3% | |
| ARCH Venture Partners XII, LLC | 10 percent owner | 4131207 2.5541% | $7.64M | 14 | 0 | +3.29% |
| ARCH Venture Partners X, LLC | 10 percent owner | 3624143 2.2406% | $6.7M | 1 | 0 | <0.0001% |
| Gosebruch Henry O | President & CEO | 15000 0.0093% | $27,750.00 | 1 | 0 | <0.0001% |
$100,473,344 | 83 | 9.53% | $328.89M | |
$5,911,307 | 70 | -1.38% | $283.54M | |
$69,130,029 | 69 | 25.63% | $307.19M | |
$87,639,490 | 62 | 18.37% | $322.84M | |
$613,304,943 | 46 | 11.85% | $291.25M | |
$24,384,691 | 42 | -30.27% | $330.92M | |
$17,983,739 | 41 | 102.87% | $284.73M | |
$109,415,500 | 33 | 18.13% | $294.45M | |
Neumora Therapeutics, Inc. Common Stock (NMRA) | $63,049,419 | 31 | 2.87% | $299.23M |
$16,271,606 | 27 | 24.11% | $314.47M | |
$2,484,989 | 17 | -17.86% | $297.87M | |
$104,137,421 | 15 | 21.28% | $327.52M | |
$7,254,955 | 14 | 20.70% | $336M | |
$12,110,219 | 14 | 336.38% | $284.23M | |
$133,369,382 | 10 | 5.02% | $301.74M | |
$8 | 2 | 28.83% | $289.81M | |
$26,374 | 2 | -53.61% | $310.54M | |
$63,731 | 1 | -19.50% | $288.65M | |
$102,796 | 1 | -21.40% | $287.55M |
| Increased Positions | 63 | +34.43% | 16M | +20.1% |
| Decreased Positions | 80 | -43.72% | 26M | -33.57% |
| New Positions | 32 | New | 9M | New |
| Sold Out Positions | 50 | Sold Out | 15M | Sold Out |
| Total Postitions | 166 | -9.29% | 68M | -13.46% |
| Fmr Llc | $6,083.00 | 4.84% | 7.84M | +89,421 | +1.15% | 2024-12-31 |
| Softbank Group Corp. | $5,076.00 | 4.04% | 6.54M | -1M | -13.33% | 2024-12-31 |
| Blackrock, Inc. | $4,931.00 | 3.92% | 6.35M | -752,463 | -10.59% | 2025-03-31 |
| T. Rowe Price Investment Management, Inc. | $3,882.00 | 3.09% | 5M | -225,534 | -4.31% | 2024-12-31 |
| Vanguard Group Inc | $3,548.00 | 2.82% | 4.57M | +195,142 | +4.46% | 2024-12-31 |
| Mic Capital Management Uk Llp | $3,462.00 | 2.75% | 4.46M | 0 | 0% | 2024-12-31 |
| Siren, L.L.C. | $3,411.00 | 2.71% | 4.4M | +2M | +68.66% | 2024-12-31 |
| Deep Track Capital, Lp | $3,104.00 | 2.47% | 4M | +3M | +604.93% | 2024-12-31 |
| Capital International Investors | $2,871.00 | 2.28% | 3.7M | +3M | +692.06% | 2024-12-31 |
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | $2,568.00 | 2.04% | 3.31M | 0 | 0% | 2025-03-31 |